AcLys-PABC-VC-Aur0101
Code | Size | Price |
---|
TAR-T17357-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T17357-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC[1].
CAS:
1438851-17-2
Molecular Weight:
1318.67
Purity:
0.98
SMILES:
[C@H]([C@H](C(N[C@@H](CC1=CC=CC=C1)C2=NC=CS2)=O)C)(OC)[C@]3(N(C(C[C@H]([C@@H](N(C([C@@H](NC(C(NC(OCC4=CC=C(NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC(C)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C4)=O)(C)C)=O)C(C)C)=O)C)[C@H](CC)C)OC)=O)CCC3)[H]
References
Costa MJ, et al. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019 Feb 21;9(1):2443.